We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Of Angiomax In Infants Under Six Months With Thrombosis

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00043277
First Posted: August 8, 2002
Last Update Posted: February 1, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
The Medicines Company
August 7, 2002
August 8, 2002
February 1, 2006
August 2002
Not Provided
Observation of improvement for thrombosis or by clinical exam such as: Decrease in size of thrombus, restoration of flow through an occluded vessel, decrease in diameter of extremity or head.
Not Provided
Complete list of historical versions of study NCT00043277 on ClinicalTrials.gov Archive Site
In addition, efficacy will also be judged by demonstrating a decrease in the molecular markers of thrombin generation.
Not Provided
Not Provided
Not Provided
 
Study Of Angiomax In Infants Under Six Months With Thrombosis
Pilot Dose Finding And Efficacy Study Of Angiomax® (Bivalirudin) As Primary Anticoagulation In Infants Under Six Months With Thrombosis

The goals of this study are:

  1. To assess the safety of bivalirudin in infants under six months with arterial or venous thrombosis;
  2. To determine the dose of bivalirudin required to achieve adequate anticoagulation as measured by the activated clotting time (ACT) or activated partial thromboplastin time (aPTT) in Infants Under Six Months with arterial or venous thrombosis;
  3. To determine the outcome of patients on bivalirudin with respect to thrombus resolution and bleeding complications compared to patients on unfractionated heparin (UH) or low molecular weight heparin (LMWH).

The goals of this study are:

  1. To assess the safety of bivalirudin in infants under six months with arterial or venous thrombosis;
  2. To determine the dose of bivalirudin required to achieve adequate anticoagulation as measured by the activated clotting time (ACT) or activated partial thromboplastin time (aPTT) in Infants Under Six Months with arterial or venous thrombosis;
  3. To determine the outcome of patients on bivalirudin with respect to thrombus resolution and bleeding complications compared to patients on unfractionated heparin (UH) or low molecular weight heparin (LMWH).
Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Thrombosis
Drug: Angiomax (bivalirudin)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
25
December 2004
Not Provided

Inclusion Criteria:

  • Parent/legal-guardian has provided written informed consent before initiation of any study related procedures.
  • Objectively confirmed thrombotic event by either doppler ultrasound, echocardiogram, CT scan, MRI, MR angiogram, MR venogram, venogram or arteriogram.
  • Age less than 6 months .
  • Gestational age greater than 35 weeks
  • Expected life expectancy at least 14 days.
  • No contraindication to anticoagulation i.e. bleeding complications.

Exclusion Criteria:

  • Active or recent (less than 7 days) bleeding.
  • Known allergy to Angiomax or hirudin, or known sensitivity to any component of the product.
  • Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days of enrollment.
  • Refusal to undergo blood transfusion should it become necessary.
  • Any other disease or condition, which, in the judgment of the Investigator would place a patient at undue risk by being enrolled in the trial.
  • Baseline prolonged PT (>18 secs) or aPTT (>55 secs)
  • Platelet count < 50,000 cells/mm3
  • Birth Trauma
  • Planned or indicated surgery within 30 days
  • Major or minor bleeding event
Sexes Eligible for Study: All
up to 6 Months   (Child)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00043277
TMC-BIV-02-04
Not Provided
Not Provided
Not Provided
Not Provided
The Medicines Company
Not Provided
Principal Investigator: Guy Young, MD Children's Hospital Orange County
The Medicines Company
January 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP
To Top